2026. CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety. Journal of Medical Sciences. 21, 2 (Sep. 2026), 30–35. DOI:https://doi.org/10.51984/szn7cg42.